Publications by Type: Presentation

2015
S. Mallidi and T. Hasan, “Can ultrasound and photoacoustic imaging identifying treatment responders and predict recurrence?New England Science Symposium, vol. Poster Presentation, no. 11 April 2015. 2015.
S. Mallidi, I. Rizvi, Z. Mai, J. P. Celli, and T. Hasan, “Carbonic Anhydrase-9 (CAIX) expression as a marker to predict response of aminolevulinic acid based photodynamic therapy,” SPIE Photonics West: Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXIV, vol. Oral Presentation. pp. 9308-5, 2015.Abstract

 

B. Q. Spring, K. Watanabe, T. Matsudaira, H. Wakimoto, S. Mallidi, and T. Hasan, “Chemoresistant glioblastoma stem-like cells respond to photodynamic therapy,” SPIE Photonics West: Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXIV, vol. Oral Presentation. pp. 9308-4, 2015.Abstract

Glioblastoma stem cells (GSCs) isolated from patients with newly diagnosed disease are potent tumor initiators that express biomarkers associated with stem cells. These stem-like cells are thought to drive treatment resistance and tumor recurrence. Preclinical models suggest that the GSC subpopulation becomes enriched and re-populates the tumor milieu following conventional therapies. This talk will discuss the use of photodynamic therapy to overcome treatment resistance in a preclinical model of human GSC neurosphere cell cultures.

J. Hempstead, et al., “Enabling technology for photodynamic therapy in global health settings: battery-powered irradiation and smartphone-based imaging for ALA-PDT,” SPIE Photonics West: Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXIV, vol. Oral Presentation. pp. 9308-18, 2015.Abstract

Lack of access to effective cancer therapeutics in resource-limited settings is widely implicated in global cancer health disparities. Here we evaluate low-cost devices to enable photodynamic therapy (PDT) and associated photosensitizer imaging in regions with little or no access to electricity or medical infrastructure. We demonstrate the efficacy of a battery-powered LED-based device following aminolevulinic acid (ALA) induced accumulation of protoporphyrin IX (PpIX). We further evaluate the capability of a consumer smartphone coupled with a 405nm LED array and a PpIX emission filter to image PpIX fluorescence. Collectively this work suggests the feasibility of image-guided ALA-PDT in resource-limited settings.

T. Hasan, H. - C. Huang, I. Rizvi, S. Mallidi, A. Kalra, and J. Fitzgerald, “Exploiting PDT effects in the design of mechanism-based combination treatments,” SPIE Photonics West: Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXIV, vol. Oral Presentation. pp. 9308-2, 2015.
S. Mallidi, K. Watanabe, D. Timerman, and T. Hasan, “Utility of 3D ultrasound and photoacoustic imaging in subject stratification and treatment prediction,” 68th Annual Meeting of the MGH Scientific Advisory Committee, vol. e-Poster. 2015.
2013
H. C. Huang, et al., “Nanoparticle-Assisted, Mechanism-Based Combination Photodynamic and Irinotecan Therapy for Pancreatic Cancer,” AICHE Annual Meeting, vol. Poster Presentation. 2013.Abstract

The purpose of this study is to strategically combine two clinical-relevant, nanotechnology-based therapies to facilitate rapid clinical translation and immediately improve on the dismal statistics of pancreatic cancer (PanCa) patients. We hypothesized that benzoporphyrin derivative (BPD)-based photodynamic therapy (PDT) (Phase I/II study, solid PanCa) destroys tumor efflux transporters, which may help maintain high intracellular concentrations of Irinotecan (CPT-11) (Phase III study, metastatic PanCa) to reduce tumor burden and prolong survival. We test our hypothesis in orthotopic PanCa models.

Two types of liposomes were fabricated by adapting procedures from literature. They are: (i) Liposome with BPD in lipid bilayer (LBPD) and (ii) Liposome encapsulating CPT-11 in aqueous core (LCPT-11). Lipids (DPPC, DOTAP, Cholesterol, DSPE-mPEG at a molar ratio of 2:0.2:1.0:0.2) were mixed in chloroform (for LBPD, dissolve with 0.2 mM BPD), and the chloroform was evaporated. Lipid films were rehydrated for 2h in an aqueous solution (for LCPT-11, contain 7 mM CPT-11) with freeze thaw cycles. The resulting dispersion was extruded through polycarbonate membranes (100 nm pore size) to form unilamellar vesicles. Liposome size and polydispersity were measured by dynamic light scattering. BPD (or CPT-11) concentration was determined by UV-Vis spectroscopy. Human pancreatic cancer cells (MIA PaCa-2 or AsPC-1, ATCC) were implanted orthotopically in Swiss Nu/Nu mice (4-6 weeks old, ~25 mg) on day 0. Animals were anesthetized with Ketamine/Xylazine and the pancreas was exteriorized. Cells (1 x 106 in 50 μL of Matrigel-containing media) were injected into the pancreas using a 301/2-gauge needle, and the incision was closed with 4-0 sutures. Treatments were initiated when the tumors reach ~35 mm3 on day 9 (determined by ultrasound imaging). Tumor bearing mice were intravenously (tail vein) injected with LBPD (0.25 mg/kg) and LCPT-11 (20 mg/kg) 1h before light administration. Interstitial PDT (690 nm laser, 100mW/cm2, 75 J/cm2) was performed on the exteriorized pancreas of the anesthetized animal, and then followed by wound closure with sutures.

We have delivered reproducible LBPDs (137±9 nm) and LCPT-11s (122±5 nm), with a polydispersity index less than 0.05, were found stable for up to 3 weeks of storage. The BPD and CPT-11 loading efficiency in liposomes were found to be ~75% and ~50%, respectively. The longitudinal ultrasound monitoring of orthotopic tumor volume in response to combination LBPD-PDT and LCPT- 11 was carried out with appropriate controls. We observed that LBPD-PDT significantly enhances the tumoricidal efficacy of LCPT-11 and significantly inhibited tumor growth up to at least 3 weeks post-treatment (p < 0.05). Tumor volumes for the combination group on day 30 were ~3 fold and ~5 fold less than single treatments and no treatment groups, respectively.Photodynamic therapy (and Irinotecan chemotherapy) alone has already shown promise in treatment of PanCa in clinical studies. This study recognizes that the genetic complexity and heterogeneity of PanCa make it extremely difficult for any single treatment to impact outcome. To overcome therapy resistance, it is critical to understand the limitations of single treatment and develop new combination regimens based on interactive mechanisms. We performed pilot studies in orthotopic PanCa models that demonstrated LBPD-PDT could improve the efficacy of liposomal Irinotecan treatment. We anticipate the findings of this study, based on two clinically relevant treatments, will form the basis for rapid translation of a novel combination regimen for PanCa patients.